Daraprim (pyrimethamine)

**Override(s)**  |  **Approval Duration**
---|---
Prior Authorization  | 1 year
Quantity Limit  |  

**Medications**  |  **Quantity Limit**
---|---
Daraprim (pyrimethamine)  | 3 tablets per day

Initiation of therapy for toxoplasmosis: May approve an additional five tablets as a one-time loading dose.

**APPROVAL CRITERIA**

Requests for Daraprim (pyrimethamine) may be approved if the following criteria are met:

I. Individual is using in combination with leucovorin; **AND**

II. Individual is using to for one of the following:

A. Individual is using to treat toxoplasmosis; **AND**
B. Individual is using in combination with a sulfonamide unless contraindicated or not tolerated;

**OR**
C. Individual has a diagnosis of human immunodeficiency virus infection and is using to prevent an initial episode of toxoplasmosis (AHFS); **AND**
D. Individual has an intolerance or contraindication to trimethoprim-sulfamethoxazole (CDC/NIH/IDSA);

**OR**
E. Individual has a diagnosis of human immunodeficiency virus infection and is using to prevent recurrence of toxoplasmosis (AHFS);

**OR**
F. Individual has a diagnosis of human immunodeficiency virus infection and is using to treat or prevent recurrence of cystoisosporiasis (AHFS); **AND**
G. Individual has an intolerance or contraindication to trimethoprim-sulfamethoxazole (CDC/NIH/IDSA);
**Market Applicability**

<table>
<thead>
<tr>
<th>Market</th>
<th>DC</th>
<th>FL</th>
<th>FL</th>
<th>FL</th>
<th>GA</th>
<th>KS</th>
<th>KY</th>
<th>LA</th>
<th>MD</th>
<th>NJ</th>
<th>NV</th>
<th>NY</th>
<th>TN</th>
<th>TX</th>
<th>WA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>X</td>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>X</td>
<td>NA</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

*FHK- Florida Healthy Kids

**OR**

H. Individual has a diagnosis of human immunodeficiency virus infection and is using to prevent an initial episode or recurrence of *Pneumocystis jiroveci* pneumonia (AHFS); **AND**

I. Individual has an intolerance or contraindication to trimethoprim-sulfamethoxazole (CDC/NIH/IDSA).

Daraprim (pyrimethamine) may **not** be approved for the following:

I. Individual has a diagnosis of megaloblastic anemia due to folate deficiency.

**State Specific Mandates**

<table>
<thead>
<tr>
<th>State name</th>
<th>Date effective</th>
<th>Mandate details (including specific bill if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Key References:**


DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: